For example, trastuzumab (anti-HER2 monoclonal antibody) and other related medications at least doubled median survival time in patients with metastatic HER2-positive breast cancer (Hudis, 2007; Nahta and Esteva, 2007). The gene discussed is ERBB2; the disease is breast cancer.